Evidence map›Paper›PMID 33499754›Full record

Trial reportAIDS research and human retroviruses2021

Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure.

Tariro Chawana, Charles Nhachi, Kusum Nathoo, Bernard Ngara, Hideaki Okochi, Alexander Louie, Karen Kuncze, David Katzenstein, John Metcalfe, Monica Gandhi

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS research and human retroviruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Tariro ChawanaDepartment of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Charles NhachiDepartment of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Kusum NathooDepartment of Paediatrics, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Bernard NgaraDepartment of Community Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Hideaki OkochiDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Alexander LouieDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Karen KunczeDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
David KatzensteinDepartment of Medicine, Division of Infectious Diseases, Stanford University, Stanford, California, USA.
John MetcalfeDepartment of Medicine, Division of Pulmonary and Critical Care, University of California San Francisco, San Francisco, California, USA.
Monica GandhiDepartment of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
University of Zimbabwe · ZWUniversity of California, San Francisco · USGlobal Solutions for Infectious Diseases · USStanford University · US

Funding

Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention TrialsR01AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2012 to 2021
$5.6M
African Training Program for Research in AIDS & TBU2RTW007367 · FIC · BIOMEDICAL RESEARCH &TRAINING INSTITUTE · PI MASON, PETER ROBERT · 2005 to 2014
$4.8M
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infectionR01AI123024 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA, METCALFE, JOHN ZAPATA · 2016 to 2020
$3.6M
Training for Research Excellence and MeNtorship in Tuberculosis (TRENT)D43TW009539 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI METCALFE, JOHN ZAPATA · 2013 to 2022
$2.9M
African Program for Research training in HIV, TB and associated opportunistic infU2RTW006878 · FIC · STANFORD UNIVERSITY · PI KATZENSTEIN, DAVID ALLENBERG · 2005 to 2009
$747k
FIC NIH HHS D43 TW009539FIC NIH HHS U2R TW006878FIC NIH HHS U2R TW007367NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI098472NIAID NIH HHS R01 AI123024
6 · The paper itself

Abstract

Objective methods of measuring antiretroviral adherence are limited. We assessed the relationship between tenofovir disoproxil fumarate (TDF) hair concentrations, self-reported adherence, and virological outcomes in HIV-infected adolescents in Harare, Zimbabwe. HIV-infected adolescents on atazanavir/ritonavir-based second-line treatment for >6 months with viral load (VL) ≥1,000 copies/mL were randomized to either modified directly administered antiretroviral therapy (mDAART) or standard of care. Hair and VL samples were collected at baseline and after 90 days. Treatment outcome was defined as TDF concentrations in hair. Virological suppression was defined as VL <1,000 copies/mL. Thirty-four adolescents had TDF concentrations measured at baseline and follow-up. Mean (median); range age was 16 (16); 13-18 years and 53% were females. Nineteen (56%) were randomized to mDAART. Mean (SD); range TDF concentrations were 0.03 (0.04); 0-0.17 ng/mg hair and 0.06 (0.06); 0-0.3 ng/mg hair at baseline and follow-up, respectively. Higher TDF concentrations were associated with decreased VL [regression coefficient (RC) 0.8; 95% confidence interval (CI) 0.7-1.0;

Indexed as

Anti-HIV AgentsHIV InfectionsTenofovirViral LoadAdolescentFemaleHairHumansMaleMedication AdherenceSelf ReportTreatment FailureZimbabweAnti-HIV AgentsTenofoviradolescentstenofovir hair concentrationsvirological treatment failure

Identifiers

PMID33499754
PMCPMC8573801
OpenAlexW3122351067

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.